603367 辰欣药业
2025/09 - 九个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入2,583,780-13.94%3,981,5724,462,3494,066,0883,782,593
减:营业总成本2,227,109-14.86%3,483,4633,866,6833,717,6183,536,814
    其中:营业成本1,160,604-9.70%1,729,0941,839,0241,789,2931,684,647
               财务费用(18,539)-21.94%(32,483)(33,671)(27,876)(9,084)
               资产减值损失(59,777)51.01%(56,026)(73,497)(16,462)(21,297)
公允价值变动收益23,866-3.94%10,528(10,375)(3,120)(6,090)
投资收益98,427316.41%62,30444,11818,68072,513
    其中:对联营企业和合营企业的投资收益6150,107.67%(484)132(753)4,166
营业利润424,293-2.64%572,048592,578364,583334,421
利润总额423,310-3.56%575,773595,857366,191336,132
减:所得税费用38,0706.97%60,83370,43013,9202,230
净利润385,240-4.49%514,940525,426352,271333,902
减:非控股权益3,228-38.32%6,0344,0882,313(245)
股东净利润382,012-4.05%508,906521,338349,959334,146

市场价值指针
每股收益 (元) *0.840-4.55%1.1201.1500.7700.740
每股派息 (元) *0.188-14.55%0.4400.4360.3350.300
每股净资产 (元) *13.5905.41%13.14112.64911.76311.150
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容